Visceral Stiffness Measurement Using Acoustic Radiation Force Impulse

Clinical Application of the Spectrum of Visceral Stiffness Measurement Using Acoustic Radiation Force Impulse Technology

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01311934

Acronym

ARFI

Enrollment

200

Registered

2011-03-10

Start date

2011-03-31

Completion date

2012-02-29

Last updated

2011-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibrosis, Visceral Stiffness

Brief summary

The acoustic radiation force impulse (ARFI) technology provides real-time measurements of tissue stiffness. Aim: Using the ARFI ultrasonography, the investigators aims are to complete the correlation and validity studies between visceral ARFI quantification and the referenced Metavir fibrosis scoring and to conduct subsequent innovative studies on liver diseases.

Detailed description

Using ARFI technology, we are establishing a complete hepatic and visceral shear wave spectrum to correspond to the entire METAVIR fibrosis scoring and various functional stratifications.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* patients with chronic liver diseases who underwent liver biopsy * patients with pathologically or radiologically proven cirrhosis

Exclusion criteria

* Post major abdominal surgery * After interferon or neucleos(t)ides treatment * PBC,PSC,WD,AIH,viral coinfections * Liver abscess * Exposure to hepatotoxic drugs or chemicals * Thrombosis of splenic vein, portal veins * After resection or embolism of the spleen * Acute or chronic pancreatitis * Biopsy contraindications (not exclusive) * ARFI measurements low quality * Fibrotest contraindications: Acute hepatitides, Extrahepatic cholestasis, e.g., pancreatic cancer, gallstones, CBD\>0.7cm Severe hemolysis * Cardiac congestion * Liver cancer other than HCC * Treated HCC

Countries

Taiwan

Contacts

Primary ContactSheng-Hung Chen, MD

shcvghtc@gmail.com886422052121

Outcome results